

References

Adida C, Recher C, Raffouv E, Rousselot P, Daniel M.T, Taksin, A.L, Sigaux F, Degos L, Altieri D.C. and Dombredl, H. (2000): Expression and prognostic significance of surviving in de novo acute myeloid leukemia british journal of hepatology, 111:196-200.

Altman, A.J. (1990): Clinical features and biologic implications of acute mixed lineage (Hybrid) leukemias. AmJ. Pediat. Hematol. Oncol, 12:123-129.

Amare P, Gladstone B, Varghese C, Pai S. and Advani S. (1999): Clinical significance of cytogenetic findings at diagnosis and in remission in childhood and adult acute lymphoblastic leukemia: experience from India. Cancer Genet Cytogenet; 110:144.

Ambrosisi G, Adida C. and Altieri D.C. (1997): Anovel antiapoptosis gene, survivin, expressed in cancer and lymphoma. Nature medicine, 3:917-920.

Anguita E, Gonzalez F.A, Contra T, Martin N, Valverde F. and Villegas A. (1998): usefulness of molecular

screening in childhood lymphoblastic leukemias Sangre-Bare. 43 (1): 7-15.

Arico M, Baruchel A, Bertrand Y, Biondi A, Conter V, Eden T, gander h, gayon p, horibe k, hunger sp, janka-schaub g, masera g, nachman j, pieters r, schrappe m, schmiegelow k, valsecchi mg, pui ch (2005): The seventh International Childhood Acute Lymphoblastic Leukemia Workshop report: Palermo, Italy, January 29–30, Leukemia; 19 (7):1145-1152.

Arico M, Valsecchi M, Camitta B, Schrappe, M, Chessells J, Baruchel A, Gaynon P, Silverman L, Janka-Schaub G, Kamps W, Pui, C.H. and Masera G. (2000): Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med; 342 (14): 998-1006.

Aricò M, Valsecchi MG, Rizzari C, Barisone E, Biondi A, Casale F, et al, (2008): Long-term results of the AIEOP-ALL-95 Trial for Childhood Acute Lymphoblastic Leukemia: insight on the prognostic value of DNA index in the framework of Berlin-Frankfurt-Muenster based chemotherapy. J Clin Oncol 26 (2): 283-289.

Ashmun, R.A, Look T.W, Roberts M, Roussel M.F, Stephani S, Tsuka M.O. and Sherr C.J. (1989): monoclonal antibodies to human CSF- 1receptor (c-fms proto-oncogene product) detect epitopes on normal mononuclear phagocytes and on human myeloid leukemia blast cells Blood, 73:827-831.

Avet-Loiseau H, Mechaniaud F. and Harousseau J.L. (1995): clonal hematologic disorders in Down's syndrome A review. J. Pediatr. Hematol. Oncol. 17:19-25.

Baehner R.L. and Miller D.R. (1984): Hematologic malignancies: Leukemia and Lymphoma in blood diseases of infancy and childhood. By: Bachner R.L, Miller D.R. and Cambell W.M. (ed.) 5th ed. C.V. Mosby Company, Missouri, p. 619-625.

Bagg A. and Kallakury B.V. (1999): Molecular pathology of leukemia nad lymphoma. Am. J. Clin. Pathol. 112:576.

Behm FG, Raimondi SC, Frestedt JL et al. (1996): Rearrangement of the MLL gene confers a poor

prognosis in childhood acute lymphoblastic leukemia, regardless of presenting age. *Blood*; 87:2870-2877.

Bene, M.C.; Bernier, M. and Castoldi, G. (1999): Impact of immunophenotyping on management of acute leukemias. *Hematologic*, 48:1024.

Bennett J.M, Catovsky D, Daniel M.T, Sultan C, Flandrin G, Gattton D.A.G. and Gralnick H.R. (1976): Proposals for the classificayion of acute leukemias. *Br. J. Hematol.*, 33; 449-451.

Bergmann L, Meeithing G, Briger J, Maurer U, Brieger J, Karaka T, Wedmann E. and Holezer D. (1997): High levels of Wilm's tumor gene in acute myeloid leukemias are associated with a worse long-term gene in acute myeloid leukemias are associated with a worse long-term outcome *Blood*, 90: 1217.

Bhatia S. (2004): Influence of race and socioeconomic status on outcome of children treated for childhood acute lymphoblastic leukemia. *Curr Opin Pediatr* 16 (1): 9-14.

Bomgaars L, Geyer J.R, Franklin J, Dahi G, Park J, Winick N.J, Klenke R, Berg S.L. and Blaney S.M. (2004): Phase I trial of intrathecal liposomal cytarabine

in children with neoplastic meningitis. J. Clin Oncol; 22(19): 3916-3921.

Borowitz MJ, Devidas M, Hunger SP, Bowman WP, Carroll AJ, Carroll WL, et al, Children's Oncology Group. (2008): Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood; 111:5477-5485.

Bostrom BC, Sensel MR, Sather HN, et al, (2003): Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 101 (10): 3809-3817.

Bram, R.J. and McManus, M.J. (2000): Molecular pathogenesis. In: Nelson's Textbook of Pediatrics. By: Behrman R.E, Kliegman R.M. and Johnson H.B. (eds.) 16th ed. W.B. Saunders Company, Philadelphia, p. 1533.

Braylan R and Anderson J. (2001): Flowcytometry analysis of Haematologic Neoplasia. Faguet G, New Jersey; ch.10:217-230.

Brehm A, Miska E.A. and Mcane D.J. (1998): Retinoblastoma Protein recruits histone deacetylase to repress transcription. *Nature*, 391: 397-406.

Campana D, Van Dongen J.J.M. and Pui C.H. (1999): Minimal residual disease. In childhood leukemias By: Pui, C-H, (ed.) 1ST ed. Cambridge University Press. USA. p. 413.

Campose L, Rouault J.P, Sabido O, Roubi N, Vasselon C, Magaud J.P. and Archimaud A. (1993): High expression of Bcl-2 protein acute myeloid leukemia cells is associated with poor response to chemotherapy. *Blood*, 81:3091.

Carroll WL, Bhojwani D, Min DJ, et al, (2003): Pediatric acute lymphoblastic leukemia. *Hematology (Am Soc Hematol Educ Program)*: 102-131.

Carter T.L, Paul R, Kumar W.R, Burton Gh, Harld N, Baker D.L. and Kees U.R. (2001): Hemizygous p16^{ink41} deletion in pediatric acute lymphoblastic leukemia predicts independent risk of relapse *Blood*, 97:572-600.

Cavé H, van der Werff ten Bosch J, Suciu S, et al, (1998): Clinical significance of minimal residual disease

in childhood acute lymphoblastic leukemia. N Engl J Med 339:591-598.

Chan, K.W. (2002): Acute lymphoblastic leukemia. Curr. Probl. Pediatr. Adolesc. Health care; 32 (2): 40-49.

Chessells J.M, Harrison G, Lilleyman J.S, Bailey C.C. and Richards S.M. (1997): Continuing (maintenance) therapy in lymphoblastic leukaemia: lessons from MRC UKALL X. Br J Haematol; 98(4): 945-951.

Childhood, ALL Collaborative Group (1996): Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukaemia: overview of 42 trials involving 12 000 reandomised children. Lancet; 347 (9018): 1783-1788.

Ching-Hon and Pui M.D. (2003): Presenting clinical and laboratory features of 2209 children with newly diagnosed ALL tested consecutively at St. Jude children's Research hospital (1962-1996). Cambridge University Press.

Ciampi A, Hogg SA, Kates L. (1986): Stratification by stepwise regression, corresponding analysis, and recursive partitioning: a comparison of three models of

survival analysis with covariates. Comput Stat Data Anal; 4:185-204.

Cnattingius S, Zack M.M. and Ekbon A. (1995): Prenatal and neonatal risk factors for childhood lymphatic leukemia. J. Natl. Cancer Inst., 87:908.

Consolini R, Legitimo A, Rondelli R, et al, (1998): Clinical relevance of CD10 expression in childhood ALL. The Italian Association for Pediatric Hematology and Oncology (AIEOP). Haematologica 83 (11): 967-973.

Cotran Rs, Kumar V. and Robbins S.L (1999): Robins pathologic basis of disease By: W.B. Saunders Company, (6th ed), p. 464 and 648.

Coustan-Smith E, Sancho J, Hancock ML, et al, (2000): Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood 96:2691-2696.

Crist WM and Smithson WA. (2000): The leukemias. In Nelson text book of pediatrics. Behrman RE, Kliegman RM, and Jenson H.B (eds.), 16th edition, Volume 4, Chapter 502; p.1543-1546.

Crist WM, Carroll AJ, Shuster JJ, Behm FG, Whitehead M, Vietti TJ. (1990b): Poor prognosis of children with pre-B acute lymphoblastic leukemia is associated with the t (1; 19) (q23; p13): a Pediatric Oncology Group study. *Blood* 76: 117-122.

Crist WM, Carroll AJ, Shuster JJ, et al, (1990a): Philadelphia chromosome positive childhood acute lymphoblastic leukemia: Clinical and cytogenetic characteristics and treatment outcome-A Pediatric Oncology Group study. *Blood* 76:489-494.

Curney J.G, Davis S. and Severson A. (1996): Trends in cancer incidence among children in the U.S. *Cancer*, 78:532.

Dacie J.V. and Lewis S.M. (1981): Bone marrow technique of needle aspiration biopsy of bone marrow. In: *Practical hematology*. 6th edition. p. 117 Churchill Livingstone Edinburgh.

Delgado R.F. and Patte C. (1999): Lymphoid malignancies in childhood in: *Textbook of Malignant Hematology*. By: Degos, L. Inch, D.C. and Lowenberg, B. (eds.) 1sted. Martin Dunitz Ltd. Uk, p.519-530.

Delia D, Aiello A, Soligo D. and Pezzella F. (1992): Bcl-2 Proto-Oncogene expression in normal and in neoplastic human myeloid cells. *Blood*, 79:1291.

Deveraux Q.L. and Reed J.C. (1999): IAP family Proteins-suppressor of apoptosis. *Genes and Development*, 13:239.

Dini G, Cornish J.M. and Gardner H. (1996): Bone Marrow Transplant indications for childhood leukemias: Achieving a consensus. The EBMT Pediatric Disease Working Party. *Bone Marrow Transplant*, 18 (Suppl.2):4.

Dordelmann M, Reiter A, Borkhardt A, Ludwig WD, Gotz N, Viehmann S. (1999): Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. *Blood* 94 (4): 1209-1217.

Drexler H.G, Theil E. and Ludwig W.D. (1991): Review of the incidence and clinical relevance of myeloid antigen-positive acute lymphoblastic leukemia. *Leukemia*, 5(8):637-648.

El Attar I. Cancer Registration NCI 2001.at:
<http://www.nci.edu.eg/Journal/nci2001%20.pdf> accessed:
Feb, 2006.

El Diery W.S, Tokino T. and Levy D.B. (1993): WAF-1
apoptestial mediator of p53 tumor suppression. Cell
75:817.

El Nadi IM, (2002): Protocol Therapy for newly
diagnosed ALL patients with difficult Risk Groups. M.D.
Thesis.

***El-Kerdany A.T, Abdel-Gaffar A, Hashem A, Zaki M,
Fayad A, Kenawy N. and Khalifa a. (2001):*** Wilms
Tumor (WTI) GENE Expression in Acute Childhood
Leukemia: Its Relation to Standard Prognostic Factors,
Vol. 18 No.1, 185-206.

El-Masry m. and hashem t. (2001): monitoring tumor
cell purge by long term marrow culture in acute
leukemia. Journal of the Egyptian Nat. cancer inst.;
13(3): 167:173.

Evans WE, Crom WR, Abromowitch M et al, (1986):
Clinical pharmacodynamics of high-dose methotrexate in
acute lymphocytic leukemia. Identification of a relation

between concentration and effect. N Engl J Med; 314:471-477.

Evans WE, Relling MV, Rodman JH, et al, (1998): Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med 338:499-505.

Fahri D.C. and Rosenthal N.S. (2000): Acute lymphoblastic leukemia in: Clinicsin Laboratory Medicine. By: Crisan D. (ed.) W.B. Saunders Company, Philadelphia, 20 (1):17.

Ferra F. and Delvecchio L. (1992): Clincial relevance of acute mixed-lineage leukemia. Blood, 79; 2799.

Flandrin G and Daniel MT. (1981): Cytochemistry in classification of leukemias.In: the leukemic cell. Catovsky, D. (ed.) p: 44; Churchill Livingstone, New York.

Fletcher JA, Kimball VM, Lynch E et al, (1989): Prognostic implications of cytogenetic studies in an intensively treated group of children with acute lymphoblastic leukemia. Blood; 74:2130-2135.

Fletcher JA, Lynch EA, Kimball VM et al, (1991): Translocation (9;22) is associated with extremely poor prognosis in intensively treated children with acute lymphoblastic leukemia. *Blood*; 77:435-439.

Flipovich A.H, Mathur A. and Kamat D. (1994): Lymphoproliferative disorders and other tumors complicating immunodeficiencies. *Immunodeficiency*, 5:91.

Flohr T, Schrauder A, Cazzaniga G, Panzer-Grümayer R, van der Velden V, Fischer S, et al, (2008): International BFM Study Group (I-BFM-SG). Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. *Leukemia*; 22:771-782.

Gad El-Mawla, N. (1996): A report on results of treatment protocol. 841 of ALL patients. Personal communications.

Gadalla A. (1996): Profile in childhood cancer in National Cancer Institute from 1975-1994. Msc. Thesis of Pediatrics, National Cancer Institute. Cairo University.

Gajjar A, Harrison PL, Sandlund JT, et al, (2000): Traumatic lumbar puncture at diagnosis adversely affects outcome in childhood acute lymphoblastic leukemia. Blood 96 (10): 3381-3384.

Gajjar A, Ribeiro RC, Hancock M.L, Rivera G.K, Mahmoud H, Sandlund J.T, Crist W.M. and Pui C.H. (1995): Persistence of circulating blasts after 1 week of multiagent chemotherapy confers a poor prognosis in childhood ALL. Blood; 86: 1292-1295.

Gajjar A, Ribeiro RC, Mahmoud HH et al, (1996): Overt testicular disease at diagnosis is associated with high risk features and a poor prognosis in patients with childhood acute lymphoblastic leukemia. Cancer; 78:2437-2442.

Gale R.P. and Ben-Bassat I. (1987): Hybrid acute leukemia. Br. J. Hematol., 65:261.

Gaydos L, Freireich E. and Mantel N. (1962): the quantitative between platelet count and hemorrhage in patients with acute leukemia. N. Engl. J. Med., 266:905.

Gomez-Almaguer, D Ruiz-Arguelles G.J. and Ponce-de-Leon S. (1998): Nutritional status and socioeconomic conditions as prognostic factors in the outcome of therapy in childhood acute lymphoblastic leukemia. Int. J. Cancer, (Suppl.) 11:52.

Greaves M. (1986): Differentiation - Linked leukemogenesis in lymphocytes. Science. 243:697.

Greaves M. (1988): Speculations on the cause of childhood acute lymphoblastic leukemia. Leukemia, 2:120.

Greaves MF, Janossy G, Peto J, Kay H. (1981): Immunologically defined subclasses of acute lymphoblastic leukaemia in children: their relationship to presentation features and prognosis. Br J Haematol; 48:179-197.

Griffin T.C, Shuster J.J, Buchanan G.R. et al., (2000): Slow disappearance of peripheral blood blasts is an adverse prognostic factor in childhood T cell acute

lymphoblastic leukemia: a pediatric Oncology Group study. *Leukemia* 14(5): 792-795.

Hammond G, Sather H. and Bleyer W. (1997):
Stratification by prognostic factors in the design and analysis of clinical trials for acute leukemia. By: Buchner T, Schellong G, Hiddemann W, Urbaniz D. and Ritter J. (eds.) Erlin Springer-Verlag. p. 161.

Hamza Mr, Ibrahim A, Mansour M, et al, (1982):
Clinicopathologic study of leukemia. Analysis of 220 managed at NCI. *J Egypt* 1:29.

Hany H, Iman S, Shreif Aboul N, et al, (2004):
Outcome and Prognostic Factors of Acute Lymphoblastic Leukemia in Children at the National Cancer Institute, Egypt. *Journal of Pediatric Hematology/Oncology*. 26(8): 507-514.

Harris MB, Shuster JJ, Carroll A, et al, (1992):
Trisomy of leukemic cell chromosomes 4 and 10 identifies children with B-progenitor cell acute lymphoblastic leukemia with a very low risk of treatment failure: a Pediatric Oncology Group study. *Blood* 79 (12): 3316-3324.

Harris N.L, Jaffe E, SDiebold J, Flandrin G, Muller-Hermelink H.K, Vardiman J, Lister T.A. and Bloomfield (2000): The world health Organization of neoplasms of the hematopoietic and lymphoid tissues. Hematology J., 1:53.

Harrison CJ, Moorman AV, Barber KE, et al, (2005): Interphase molecular cytogenetic screening for chromosomal abnormalities of prognostic significance in childhood acute lymphoblastic leukaemia: a UK Cancer Cytogenetics Group Study. Br J Haematol 129 (4): 520-530.

Heerema NA, Nachman JB, Sather HN, Sensel MG, Lee MK, Hutchinson R. (1999): Hypodiploidy with less than 45 chromosomes confers adverse risk in childhood acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 94 (12): 4036-4045.

Helen E. and Heslop M.D. (2000): Gene therapy of pediatric leukemia in: Clinics in Laboratory Medicine. By: Crisan, D. (ed.) W.B. Saunders Company, Philadelphia, 20(1): 139.

Hurwitz CA, Silverman LB, Schorin MA, Clavell LA, Dalton VK, Glick KM, Gelber RD, Sallan SE. (2000): Substituting Dexamethasone for Prednisone Complicates Remission Induction in Children with Acute Lymphoblastic Leukemia. *Cancer*; 88(8):1964-1969.

Hussein H M.D, Sidhom I, M.D, Abou El Naga S, M.D, Zamzam M, M.D. et al, (2003): survival and prognostic factors of acute lymphoblastic leukemia in children at the National Cancer Institute. Egypt. (*Journal of the Egyptian NCI*).

ISCN. (1995): an international system for human cytogenetic nomenclature. Mitelman F, editor. Basel, Switzerland: S. Karger.

Jackson JF, Boyett J, Pullen J, et al, (1990): Favorable prognosis associated with hyperdiploidy in children with acute lymphocytic leukemia correlates with extra chromosome 6. A Pediatric Oncology Group study. *Cancer*; 66:1183-1189.

Kadan-Lottick NS, Ness KK, Bhatia S, et al, (2003): Survival variability by race and ethnicity in childhood

acute lymphoblastic leukemia. JAMA 290 (15): 2008-2014.

Kamps WA, Bokkerink JP, Hakvoort-Cammel FG, et al, (2002): BFM-oriented treatment for children with acute lymphoblastic leukemia without cranial irradiation and treatment reduction for standard risk patients: Results of DCLSG protocol ALL-8 (1991-1996). Leukemia 16:1099-1111.

Kay M.A, Lin D. and Hoogerbrugge P.M. (1997): Gene therapy Proc. Natl. Acad. Sci. USA, 94: 12744.

Kersey, John H. (1997): Fifty Years of Studies of the biology and therapy of childhood leukemia. Blood, Vol 90, No 11: p. 4243-4251.

Khalidi H.S, Chang K.L, Medeiros L.J, Brvenes P.K, Slovac M.L, Murata-Collins J.L. and Arber D.A. (1999): Acute lymphoblastic leukemia Survey of immunophenotype, French – American – British classification, frequency of myeloid antigen expression, and karyotypic abnormalities in 210 pediatric and adult cases. Am J. Clin. Pathol. 111- 467.

Khalifa A.S, Anwar W, Tantawy A.G, Slama I.D. and Ezzat MH. (1999): Changing pattern of childhood acute leukemia in Pediatric-Hematology-Oncology unit. Ain Shams University. Egypt. J. of Pediatrics 16, No. (1, 2), 207-231.

Kieldsberg C, Kathryn F, Johnson K.E, Hussong J, Mckennu K, Perkins S, Peterson P. and Rodgers G. (2000): Acute myeloid leukemia. In: Practical diagnosis of hematologic disorders (third edition) chapter 27, p. 399.

Kim TH, Hargreaves HK, Byrnes RK et al, (1981): Pretreatment testicular biopsy in childhood acute lymphocytic leukemia. Lancet; 2:657-658.

King-Underwood L. and Pritchard-Jones, K. (1998): Wilm's tumor (TWI) gene mutations occur mainly in acute myeloid leukemia and may confer drug resistance. Blood, oncol (80:2961).

Kiny E. and Leukens J.N. (2000): Classification and differentiation of the acute leukemia. In: wintrobe's clinical hematology. By: Greer, J.p. and Rodgers, G.M.

(ed) tenth ed. Williams and Wilkins Company Baltimore, p. 2209.

Koren G, Ferrazini G, Sulh H et al, (1990): Systemic exposure to mercaptopurine as a prognostic factor in acute lymphocytic leukemia in children. N Engl J Med; 323:17-21.

Kurtzberg J, Ernst T.J, Keating M.J, Gandhi V, Hodge J.P, Kisor D.F Lager J.J, Stephens C, Levin J, Krenitsk T, Elion G. and Mitchell B.S. (2005): Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. J Clin Oncol; 23(15): 3396-3403.

Lanzowsky P. (2011): Leukemia in: Manual of pediatric Haematology and oncology, fifth edition p: 359-409 Academic press, San Diego, San Francisco, New York, Boston, London, Sydney and Tokyo.

Li F, Ackermann E.J, Bennett C.F, Rothermel A.I, Plescia J. and Villa A. (1999): Pleiotropic cell division defects and apoptosis induced by interference with surviving function. Nature cell biology, 1: 461.

Liang D.C, Hung I.J, YUang C.P, Lin K.H, Chen J.S, Hsiao T.C, Chang T.T, Pui C.H Lee C.H. and Link K.S. (1999): Unexpected mortality from the use of E. coli L-asparaginase during remission induction therapy for childhood acute lymphoblastic leukemia: a report from the Taiwan pediatric oncology Group. *Leukemia*; 13(2): 155-160.

Lichtman, M.A. (1995): Acute myelogenous leukemia in: *Williams Hematology*. By: Beutler E, Lichtman, M.A. Coller, B.S. and Kipps, T.J. (eds) 5th McGraw - Hill Companies, USA, p.272.

Lilleyman J.S, Hann I.M. and Stevens R.F. (1992): Cytomorphology of childhood lymphoblastic leukemia: A prospective study of 2000 patients. *Br. J. Hematol.*; 81:52.

Lilleyman, J.S. (1999): clinical importance of speed of response to therapy in childhood ALL, *Medline*.

Linnet M.S, Hatch E.E. and Kleinerman R.A. (1997): Residential exposure to magnetic fields and acute lymphoblastic leukemia in children *N. Engl. J. Med.* 337:1.

Lodish H, Berk A, Zipursky S.L, Matsudaira P, Baltimore D. and Darnell J.E. (2000): Regulation of eukaryotic cell cycle in Molecular cell Biology. By: Fruin, W.H. (ed). 4th ed. W.B. Saunders Company, Philadelphia, p. 526.

Löffler H. and Gassmann W. (1994): Morphology and Cytochemistry of acute lymphoblastic leukemia. Bailliere's clinical Hematology; 7(2): 263-272.

Margolin J. and Poplack D. (1997): Acute lymphoblastic leukemia. In: Pizzo P. and Poplack D. (eds): Principles and practice of Pediatric Oncology (3rd ed) New York, Lippincott-Raven, p409.

Margolin J. and Poplack D. (2006): Acute lymphoblastic leukemia 4th ed. Philadelphia Lippin, at Williams AND Wilkins PP 789-814.

Mazure E.M, Wittels E.G. and Schiffman F.K. (1986): Hand mirror cell lymphoid leukemia in adults Cancer, 57:92.

Miller K.B. (1995): clinical manifestation of AML. In hamtology Basic Principles and Practice. BY: Hoffman R, Benz E.J, Schatill S.J, Furie B, Cohen H.J. and

Silberstein L.M. (eds) 2nd ed. Churchill Livingstone, New York, p. 1000.

Miller R. (1971): Death from childhood leukemia and solid tumours among twins and other sibs in the United States. J. Natl. Cancer Inst., 46:203-310.

Mitchell CD, Richards SM, Kinsey SE, et al, (2005): Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial. Br J Haematol 129 (6): 734-745.

Mitelman F. ISCN. (1995): An International System for Human Cytogenetic Nomenclature. Basel, Switzerland: S. Karger.

Nachman J, Sather HN, Buckley JD et al, (1993): Young adults 16-21 years of age at diagnosis entered on Children's Cancer Group acute lymphoblastic leukemia and acute myeloblastic leukemia protocol. Results of treatment. Cancer; 71:3377-3385.

Nachman J, Sather HN, Gaynon PS, et al, (1997): Augmented BFM therapy abrogates the adverse prognostic significance of slow early response to

induction chemotherapy for children and adolescents with acute lymphoblastic leukaemia and unfavorable presenting features: A report from the Children's Cancer Group. *J Clin Oncol* 15:2222-2230.

Nachman JB, Sather HN, Sensel MG, Trigg ME, Cherlow JM, Lukens JN, et al, (1998): Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. *N Engl J Med*; 338:1663-1671.

National Cancer Institute Website: Pediatric Cancers at <http://www.nci.edu.eg/> accessed Feb, 2006.

Nemecek E.R. and Matthews D.C. (2002): human leukemia. *Curr Opin Hematol*; 9(4):316-321.

Neuvaut C, Maldarelli F, Schmitt T. and Majone F. (1998): Human T-cell leukemia virus type 1 Tax and cell cycle progression role of cyclin D-cdk and P11 Orb. *Mol. Cell Biol.*, 6:3620.

Pajor L, Szukai K, Mehes G, Kosztolányi G, Jaksó P, Lendvai G, Szanyi I and Kajtár P. (1998): Combined metaphase, interphase cytogenetics, and flow cytometry

analysis of DNA content of pediatric acute lymphoblastic leukemia. Cytometry 34, p. 87.

Panzer-K Grumayer ER, Schneider M, Panzer S, Fasching and Gadner H. (2000): Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia. Blood 95 (3): 790-794.

Pinheiro J.P. and Boos J. (2004): The best way to use asparaginase in childhood acute lymphoblastic leukaemia—still to be defined? Br J Haematol; 125(2): 117-127.

Pinkel D, Woo S. (1994): Prevention and treatment of meningeal leukemia in children. Blood; 84:355-366.

Polli N, Obrien M. and Tavaresde Castro J. (1984): Characterization of blast cells in chronic granulocytic leukemia, acute myelofibrosis and undifferentiated leukemia. Ultrastructural morphology and cytochemistry Br.J. Hematol., 59:277.

Preisler H.D, Kukal C. and Browman G. (1991): IL-1B expression and treatment outcome in acute myelogenous leukemia. Blood 78:849.

Preisler H.D. (1989): Proto-oncogene expression and the clinical characteristics of ANLL. A Leukemia intergroup pilot study. Blood, 73: 255.

Pui C.H, Behm FG, Downing JR, et al, (1994): 11q23/MLL rearrangement confers a poor prognosis in infants with acute lymphoblastic leukemia. J Clin Oncol; 12: 909-915.

Pui C.H. (2001): Acute lymphoblastic leukemia in: Williams's hematology. By: Ernest Beutler. Marshall A, Lichman, Barry S, Collier Thomas J, Kipps AND Uri Seligsohn (ed.), (6thed). New York, Milan, Tokyo, Toronto. Chapter 97, p. 1141.

Pui C.H. and Crist, W.M. (1999): Acute lymphoblastic leukemia. In childhood leukemias. By Pui, C-H. (ed) 1st ed. Cambridge University Press, USA, p.288.

Pui CH and Evans WE (2006): Treatment of acute lymphoblastic leukemia. N Engl J Med 354 (2): 166-178.

Pui CH and Ribeiro Raul C. (2003): International Collaboration on Childhood Leukemia. International Journal of Hematology, (78) p383-389.

Pui CH, Boyett JM, Relling MV, Harrison PL, Rivera GK, Behm FG, Sandlund JT, Ribeiro RC, Rubnitz JE, Gajjar A, Evans WE. (1999): Sex differences in prognosis for children with acute lymphoblastic leukemia. *J Clinical oncology*; 17(3):818-824.

Pui CH, Campana D, Pei D, et al, (2009): Treating childhood acute lymphoblastic leukemia without cranial irradiation. *N Engl J Med*. Jun 25; 360(26):2730-2741.

Pui CH, Carroll AJ, Raimondi SC, et al, (1990): Clinical presentation, karyotypic characterization, and treatment outcome of childhood acute lymphoblastic leukemia with a near-haploid or hypodiploid less than 45 line. *Blood* 75 (5): 1170-1177.

Pui CH, Cheng C, Leung W, Rai SN, Rivera GK, Sandlund JT, et al. (2003b): Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia. *N Engl J Med*; 349:640-649.

Pui CH, Crist WM, look AT. (1990): Biology and clinical significance of cytogenetic abnormalities in childhood acute lymphoblastic leukemia. *Blood* 76: 1449-1463.

Pui CH, Evans WE. and Pharma, D. (1998): Acute lymphoblastic leukemia. N Engl. J Med., 339: 605-615.

Pui CH, Jhon T. Sandlund, Deqing Pei, Dario Campana, et al, (2004): improved outcome for children with acute lymphoblastic leukemia: results of total therapy study XIII B at SJCRH (Blood; 104: 2690-2696).

Pui CH, Relling MV, Downing JR (1997): Acute lymphoblastic leukemia. N England J Med 336:317.

Pui CH, Rubnitz JE, Hancock ML, Downing JR, Raimondi SC, Rivera GK, Sandlund JT, Ribeiro RC, Head DR, Relling MV, Evans WE, Behm FG. (1998): Reappraisal of the clinical and biologic significance of myeloid-associated antigen expression in childhood acute lymphoblastic leukemia. J Clin Oncol; 16(12):3768-3773.

Pui CH, Sandlund JT, Pei D, et al. (2003a): Results of therapy for acute lymphoblastic leukemia in black and white children. JAMA 290 (15): 2001-2007.

Pullen J, Shuster JJ, Link M, Borowitz M, Amylon M, Carroll AJ. (1999): Significance of commonly used prognostic factors differs for children with T-cell acute

lymphocytic leukemia (ALL), as compared to those with B-precursor ALL. A Pediatric Oncology Group Study. Leukemia 13 (11): 1696-1707.

Raimondi SC, Behm FG, Roberson PK, et al, (1990): Cytogenetics of pre-B-cell acute lymphoblastic leukemia with emphasis on prognostic implications of the t(1;19). J Clin Oncol 8 (8): 1380-1388.

Raimondi SC. (1993): Current status of cytogenetic research in childhood acute lymphoblastic leukemia. Blood; 81:2237-2251.

Raza A, Preisler H.D, Larson R. And Kukla C. (1993): Biological characteristics of newly diagnosed poor prognosis acute myeloid leukemia. Am J. Hematol., 42:359.

Reiter A, Schrappe M, Ludwig WD et al, (1992): Favorable outcome of B-cell acute lymphoblastic leukemia in childhood: a report of three consecutive studies of the BFM group. Blood; 80:2471-2478.

Relling MV, Dervieieux T. (2001) : Pharmacogenetics and cancer therapy. Nat Rev Cancer(2): 99-108.

Ribeiro RC, Broniscer A, Rivera GK, et al, (1997): Philadelphia chromosome-positive acute lymphoblastic leukemia in children: durable responses to chemotherapy associated with low initial white blood cell counts. *Leukemia* 11 (9): 1493-1496.

Riehm H, Feickert HJ, Schrappe M et al, (1987): Therapy results in five ALL-BFM studies since 1970: implications of risk factors for prognosis. *Hamatol Bluttransfus*; 30:139-146.

Rivera GK, Pinkel D, Simone JV, et al, (1993): Treatment of acute lymphoblastic leukemia: 30 years' experience at St Jude Children's Research Hospital. *N Engl J Med* 329:1289-1295.

Romana S.P, Poirel H, Della Valle V, Mauchauffe M, Busson-Le Coniat M, Berger R. and Bernard O.A. (1999): Molecular analysis of chromosomal breakpoints in three examples of chromosomal translocation involving the TEL gene. *Leukemia*, 13:1754.

Rosenberg N. and Krontirs, T.G. (2000): The molecular basis of neoplasia in hematology basic principles and practice. By: Hoffman R, Edward J, Benz Jr, Shutil S,

Furie B, Cohen HJ, Silberstein LE and M cGlave P (eds) 3rd ed., New York London, Philadelphia, Chapter 49, p. 870.

Ross R. and Anthomy W. (1991): Growth factors and their receptors: Genetic control and rational applications. J. of Nat. Cancer Institute, 82:874.

Rubnitz J.E. and Look A.T. (1998): Molecular genetics of childhood leukemia. J. Pediatr. Hematol. / Oncol., 20(1): 1-10.

Rubnitz J.E. and Look A.T. (2000): Pathology of acute lymphoblastic leukemia. In: Hematologic Basic Principles and Practice. By Hoffman R, Shaahil D, Furie B, Cohen H, Silberstein L. and McGlave, P. (eds). Third ed. Churchill Livingstone N.Y., P. 1052.

Rubnitz JE, Downing JR, Pui CH et al, (1997): TEL gene rearrangement in acute lymphoblastic leukemia. a new genetic marker with prognostic significance. J Clin Oncol; 15: 1150-1157.

Rubnitz JE, Link MP, Shuster JJ, et al, (1994): Frequency and prognostic significance of HRX

rearrangements in infant acute lymphoblastic leukemia: a Pediatric Oncology Group study. *Blood* 84 (2): 570-573.

Sallan SE, Ritz J, Pesandro J et al, (1980): Cell surface antigens: prognostic implications in childhood acute lymphoblastic leukemia. *Blood*; 55:395-402.

Sandler D.P. and Ross J.A. (1997): Epidemiology of acute leukemia in children and adults. *Semin Oncol.*, 24:3.

Sanz M.A. and Sepra A. (1996): Immunophenotyping of AML and MDS and detecting of residual disease in *Baillier's clinical hematology*, Baillier's Tandall, 9:1.

Scheinberg D.A. and Gold D.W. (1994): The leukemias, In: *Harrison's Principles of Int. Medicine*. By: Isselbacher, K.J, Braunwald E, Wilson J.D, Martin J.B, Fauci A.S. and Kasper D.L. (eds.) 13th ed. McGraw Hill Inc. Health Professions Divisions, New York P.1764.

Schrapppe M, Reiter A, Ludwig WD, Harbott J, Zimmermann M, Hiddemann W, Riehm H (2000): Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: Results of trial ALL-BFM 90-

German-Austrian-Swiss ALL-BFM Study Group. Blood 95:3310-3322.

Schultz K.R, Massing B. and Spindelli J.J. (1997): Importance of the day 7 bone marrow biopsy as a prognostic measure of the outcome in children with acute lymphoblastic leukemia. Med. Pediatr. Oncol. 29:16.

Schumacher HR, Alvares CJ, Blough RI, and Mazzella F. (2002): Acute Leukemia: Clinical Lab Med; 22(1):153-192.

Seeger K, Viehmann S, Buchwald C, Harbott J, Schrappe M, Stary J, Henz G, and Trka J. (2001): Treatment response and residual disease monitoring in initial and relapsed TEL-AML1-positive acute lymphoblastic leukemia in childhood. Leukemia, 15(2): 280.

Seer A. (1998): Cancer institute review, 1973-1995, National Cancer Institute.

Shah Np, Tran C, Lee FY, Chen P, Norris D, Sawyers CL (2004): Overriding imatinib resistance with a novel ABL kinas inhibitor. Science; 305 (5682):399-401.

Sherr C.J. and Roberts J.M. (1995): Inhibitors of mammalian G₁-cyclin-dependent kinase. *Genes Dev*, 9:1149.

Smith MA, Ries LA, Gurney J G, et al (1999): cancer incidence and survival among children and adolescents. National cancer institute, SEER Program, 1999. NIH Pub No 99-4649.PP17-34.

Sonneveld P. and Wiemer E. (1997): Assays for the analysis of –P-glycoprotein in acute myeloid leukemia and CD34 subsets of AML blasts. *Leukemia*, 11:1160.

Steinherz PG, Gaynon PS, Breneman JC, et al, (1996): Cytoreduction and prognosis in acute lymphoblastic leukemia--the importance of early marrow response: report from the Childrens Cancer Group. *J Clin Oncol* 14 (2): 389-398.

Stock W. and Thirman M.J. (2000): Pathology of acute myeloid leukemia. In *Hematology basic principles and practice*. By: Ronal H, Edward J. Berz Jr, Sanford J, Brucefuric (eds), (3rd ed) New York Milan, Tokyo, Toronto, Chapter 52, p. 979.

Tanaka K.I, Wamoto S, Gon G, Vohara T, Iwamoto M. and Tanigawa N. (2000): Expression of surviving and its relationship to loss of apoptosis in breast carcinomas. Clinical Cancer Research, 6:127.

Trueworthy R, Shuster J, Look T, et al, (1992): Ploidy of lymphoblasts is the strongest predictor of treatment outcome in B-progenitor cell acute lymphoblastic leukemia of childhood: A Pediatric Oncology Group study. J Clin Oncol 10:606-613.

Tsuchida M, Ikuta K, Hanada R, Saito T, Isoyama K, Sugita K, Toyoda Y, Manabe A, Koike K, Kinoshita A, Maeda M, Ishimoto K, Sato T, Okimoto Y, Kaneko T, Kajiwara M, Sotomatsu M, Hayashi Y, Yabe H, Hosoya R, Hoshi Y, Ohira M, Bessho F, Tsunematsu Y, Tsukimoto I. and Nakazawa S. (2000): Long-term follow-up of childhood acute lymphoblastic leukemia in Tokyo Children's Cancer 1981-1995. Leukemia; 14(2): 2295-2306.

Tubergen GD and Bleyer A. (2004): The Leukemias: In; Behrman ER, Kliegman MR and Jenson BH Behram (eds): Nelson Textbook of pediatrics, 17th edition ediators.p.1694-1699.

Uckun FM, Sensel MG, Sather HN, et al, (1998): Clinical significance of translocation t(1;19) in childhood acute lymphoblastic leukemia in the context of contemporary therapies: a report from the Children's Cancer Group. *J Clin Oncol* 16: 527-535.

Van der Werff Ten Bosch J, Suciu S, Thyss A, Bertrand Y, Norton L, Mazingue F, Uyttebroeck A, Lutz P, Robert A, Boutard P, Ferster A, Plouvier E, Maes P, Munzer M, Plantaz D, Dresse M.F, Philippet P, Sirvent N, Waterkeyn C, Vilmer E, Philippe N. and Otten J. (2005): Value of intravenous 6-mercaptopurine during combination treatment in childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma: final results of a randomized phase III trial (58881) of the EORTC CLG. *Leukemia*; 19(5):721-726.

Van Dongen J.J.M. and Langerak A.M. (1999): Immunoglobulin and T-cell receptor gene rearrangements. In childhood leukemias. By Pui, C-H (ed) 1st ed. Cambridge University Press. USA, P. 145.

Van Dongen JJ, Seriu T, Panzer-Grümayer ER, Biondi A, Pongers-Willems MJ, Corral L, et al, (1998): Prognostic value of minimal residual disease in acute

lymphoblastic leukaemia in childhood. Lancet; 352:1731-1738.

Velculescu V.E, Maddem S.L, Zhang L, Lash A.E, Yu J, Rago G, Lat A, Wang C.J. and McDonnall T.J. (1999): Analysis of human transcriptomes Nature Genetics, 23:387.

Verma R.S. and Babu A. (1989): Banding techniques. In: R.S. Verma, Editor, Human chromosomes, Manual of techniques, Pergamon Press, New York p. 47.

Vogelstein B. and Kinzler K.W. (1993): The multistep nature of cancer. Trends in Genetics, 9:138.

Whitlock J.A. and Gaynon P.S. (1999): Acute Lymphocytic leukemia in: Wintrobe's Clinical Hematology By: Lee G.R, Foerster J, Lukens J, Paraskevas F, Greer J.P. and Rodgers G.M. (eds) 10th ed Williams and Wilkins Company, Baltimore, p. 2241.

Williams D, Harris A, Williams K, Brosius M and Lemonds W. (1989): A direct bone marrow chromosome technique for acute lymphoblastic leukemia. Cancer Genet Cytogenet 13, p. 239.

ZelezinK-Le N.J, Nucipcrl L. and Rowley J.D. (1995):
The molecular biology of myeloproliferative disorders
as revealed by chromosomal abnormalities. *Semin*
Hematol., 32: 201.

Zhang L, Taub JW, Williamson M, et al (1998):
Reduced folate carrier gene expression in childhood
acute lymphoblastic leukemia: relationship to
Immunophenotyping and ploidy >*Clin.Cancer Res* 4:
2169 – 2177.